Pharmaron

Boliang Lou is the CEO of Pharmaron. To contact Boliang Lou email at [email protected]. Or you may call +1.5023865399

The decision makers in Pharmaron are Bhaskar Guntoori, Boliang Lou, Chang-qing Cao, etc. Click to Find Pharmaron decision makers emails.

Pharmaron provides a comprehensive range of R&D services tailored for the life sciences sector. Our offerings include process development, assay development, discovery services, formulation, pharmacology, chemistry, biology, lead optimization, and biologics. Additionally, we specialize in DMPK (Drug Metabolism and Pharmacokinetics), toxicology, ADME (Absorption, Distribution, Metabolism, and Excretion), safety pharmacology, preclinical studies, analytical sciences, API (Active Pharmaceutical Ingredient) manufacturing, and chemical development.

Pharmaron supports drug development through a seamless integration of services that span from early discovery to preclinical stages. Our discovery services include target identification, lead optimization, and pharmacology studies. Once a lead compound is identified, we provide formulation development, toxicology assessments, and DMPK studies to ensure the compound's viability. Our experienced teams work collaboratively to streamline the process, ensuring that projects progress efficiently and effectively towards clinical trials.

Pharmaron primarily serves the pharmaceutical and biotechnology industries. Our clients range from large multinational corporations to small biotech firms. We also support academic institutions and research organizations that require specialized R&D services. Our expertise in various therapeutic areas, including oncology, neurology, and infectious diseases, allows us to cater to diverse client needs across the life sciences spectrum.

Yes, Pharmaron can assist clients with regulatory submissions for clinical trials. Our experienced regulatory affairs team provides guidance on the necessary documentation and compliance requirements for submissions to regulatory agencies. We help ensure that all preclinical data, including toxicology and pharmacokinetics, is well-documented and presented in a manner that meets regulatory standards, thereby facilitating a smoother transition to clinical trial phases.

Pharmaron's expertise in radiolabelled chemistry is significant for drug development, particularly in pharmacokinetic studies and imaging applications. Radiolabelled compounds are essential for understanding the distribution and metabolism of drugs within the body. Our capabilities in radiosynthesis and the development of radiolabelled compounds enable clients to conduct advanced studies that provide critical insights into drug behavior, ultimately aiding in the optimization of therapeutic candidates.

Pharmaron ensures the quality and reliability of its R&D services through a robust quality management system that adheres to international standards. We implement rigorous quality control measures at every stage of the research process, from initial development through to final testing. Our teams are composed of highly trained professionals who follow established protocols and best practices to deliver consistent, high-quality results. Additionally, we regularly engage in internal audits and external inspections to maintain compliance and continuously improve our services.